Trial Profile

A multicenter, international phase 1b randomized, double-blind, placebo-controlled clinical study to determine safety and tolerability of orally administered balomenib in adults with type 2 diabetes mellitus (T2DM)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 13 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Jan 2026 New trial record
17 Dec 2025 According to a Barinthus Biotherapeutics media release, the study received formal regulatory authorization in September and has now activated all clinical centers. With patient dosing underway, the trial is expected to enroll up to 60 participants and is designed to efficiently generate clinical data to inform both the safety profile of balomenib and its potential impact on metabolic parameters central to type 2 diabetes.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com